Navigation Links
Epizyme, Inc. to Be Added to NASDAQ Biotechnology Index (NBI) and NASDAQ Global Select Market
Date:12/20/2013

CAMBRIDGE, Mass., Dec. 20, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effective before market open on December 23, 2013.  Epizyme also announced that its common stock will be transferred to the NASDAQ Global Select Market effective January 2, 2014.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Index is the basis for the iShares NASDAQ Biotechnology Index(SM) Fund (Nasdaq: IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index.  In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges.

The NASDAQ Global Select Market is the top listing tier for NASDAQ companies, with the highest initial listing standards in the world.

About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit http://www.epizyme.com and connect with us on Twitter at @EpizymeRx.


'/>"/>
SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Epizyme, Inc. Provides Third Quarter 2013 Financial Results and Corporate Update
2. Epizyme, Inc. Reports Second Quarter 2013 Financial Results
3. Global Bulk Molding Compounds Market and China LOW-E Glass Analysis in New Research Added to DeepResearchReports.com
4. Welcome guests: Added molecules allow metal-organic frameworks to conduct electricity
5. MarketPublishers.com Added New Report on Thujone, (A + B)(SG) (CAS 2867-05-2) Market to Its Catalogue
6. MarketPublishers.com Added New Report on Silicon Nitride (CAS 12033-89-5) Market to Its Catalogue
7. MarketPublishers.com Added New Report on Chlorinated Polypropylene (CAS 68442-33-1) Market to Its Catalogue
8. MarketPublishers.com Added New Report on Sodium Nitrite (CAS 7632-00-0) Market to Its Catalogue
9. MarketPublishers.com Added New Report on Levocarnitine (CAS 541-15-1) Market to Its Catalogue
10. MarketPublishers.com Added New Report on Hydroxyethyl Starch (CAS 9005-27-0) Market to Its Catalogue
11. MarketPublishers.com Added New Report on Povidone Iodine (CAS 25655-41-8) Market to Its Catalogue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Information Management ... Web product. The upgrade represents a completely new technical foundation and is so ... offer a responsive design interface, significantly increased speed for search results, a streamlined layout ...
(Date:2/8/2016)... Feb. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its new website has ... resource–user-centric, story-driven, knowledge-based and mobile-friendly. Visit the new ... ... ... "The goal was to reimagine ...
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical ... for a host of launch activities including the identification ... this launch activity is especially high in the oncology ... Best Practices and the Role of Medical Affairs ... companies focused on oncology therapies find better ways to ...
(Date:2/4/2016)... - New FDA action date of July 22, ... July 22, 2016   --> - ...   - Lifitegrast has the potential to be the ... signs and symptoms of dry eye disease in adults ... product approved in the U.S. in the past decade indicated for the treatment of ...
Breaking Biology Technology:
(Date:1/20/2016)... 20, 2016  Synaptics Incorporated (NASDAQ: SYNA ... today announced sampling of S1423, its newest ClearPad ... small screen applications including smartwatches, fitness trackers, and ... and rectangular shapes, as well as thick and ... moisture on screen, while wearing gloves, and supports ...
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized ... small to find new ways to ensure data security ... iOS and Android that ties ... biometrics, transforming it into a hardware authorization token. Customer ... swipe their fingerprint on their KodeKey enabled device to ...
(Date:1/13/2016)... , January 13, 2016 /PRNewswire/ ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the addition ... Identification Market - Estimation & Forecast ...
Breaking Biology News(10 mins):